en · de · es · fr · pt
faq-desk.peptides7250.com › News › Cjc-1295 Structure And Mechanism — Hands-On Walkthrough

Cjc-1295 Structure And Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2026-05-29 · last reviewed 2026-06-18 · News

IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Analytical Measurement And Stability

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Related pages on this site

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Notes from published material

== Variation == Many genetic variants of the GC gene are known. They produce 6 main haplotypes and 3 main protein variants (Gc1S, Gc1F and Gc2). The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels. They have been proposed to account for some of the differences in vitamin D status in different ethnic groups, and have been found to correlate with the response to vitamin D supplementation.

The two promoters correspond to two broad categories of glucokinase function: In liver, glucokinase acts as the gateway for the "bulk processing" of available glucose, while, in the neuroendocrine cells, it acts as a sensor, triggering cell responses that affect body-wide carbohydrate metabolism.

== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DOPR's dose as 2.5 to 5 mg orally and its duration as 20 to 30 hours. It is said to have a very slow onset. The effects of DOPR have been reported to include closed-eye imagery, visuals, thinking changes, and insomnia and sleep disruption, among others. In one of the reports, it was described as a "heavy duty psychedelic", including strong and unignorable visuals.

=== Harris Conner-Healy === Harris Conner-Healy is played by Emma Kenney. She was born premature and was not expected to survive. Darlene names her Harris Conner-Healy as a tribute to all of the strong women in her family ("Harris" is Roseanne's maiden name) in the hopes that she'd have the same strength to survive. The elder of Darlene's two children, Harris is now a teenager who inherited her mother and grandmother's sarcastic humor. Having grown up in Chicago, Harris is unhappy about moving to Lanford and is resentful and hostile towards her family members. As Harris continuously acts indifferent to the needs of others in the household, Roseanne does what Darlene has not: she confronts Harris about her disrespectful behavior. Though Darlene is initially upset, she accepts Roseanne's actions as justified when she discovers that Harris has been selling stolen goods on Etsy to raise money to move back to Chicago. While Darlene is sympathetic to Harris's unhappiness, she exerts more control over her daughter's life, grounding her and demanding passwords to all of her social media accounts. There is some discrepancy in the series continuity with regard to the character's age. Darlene announced she was pregnant in a 1996 episode during season 8 of Roseanne, and Harris was born in a 1997 episode during season 9. This would make Harris 21, not a teenager, at the start of season 10 in 2018.

== History == The first example of a palladium catalyzed coupling of aryl halides with organotin reagents was reported by Colin Eaborn in 1976. This reaction yielded from 7% to 53% of diaryl product. This process was expanded to the coupling of acyl chlorides with alkyl-tin reagents in 1977 by Toshihiko Migita, yielding 53% to 87% ketone product.

Sources: en.wikipedia.org

Background from the literature

Iodine-135 is a neutron-rich isotope of iodine with a half-life of 6.58 hours, and important to nuclear reactor physics. It is produced in relatively large amounts as a fission product, and decays to xenon-135, which is a nuclear poison with the largest known thermal neutron cross section, which is a cause of multiple complications in the control of nuclear reactors. The process of buildup of xenon-135 from accumulated iodine-135 can temporarily preclude restarting a reactor that has been shut down. This is known as xenon poisoning or "falling into an iodine pit".

Lithium-ion Battery at the Encyclopædia Britannica. Degradation Mechanisms and Lifetime Prediction for Lithium-Ion Batteries, NREL, July 2015. Impact of Temperature Extremes on Large Format Li-ion Batteries for Vehicle Applications, NREL, March 2013.

=== Objectives === Recovery point objective (RPO): The point in time that the restarted infrastructure will reflect, expressed as "the maximum targeted period in which data (transactions) might be lost from an IT service due to a major incident". Essentially, this is the roll-back that will be experienced as a result of the recovery. The most desirable RPO would be the point just prior to the data loss event. Making a more recent recovery point achievable requires increasing the frequency of synchronization between the source data and the backup repository. Recovery time objective (RTO): The amount of time elapsed between disaster and restoration of business functions. Data security: In addition to preserving access to data for its owners, data must be restricted from unauthorized access. Backups must be performed in a manner that does not compromise the original owner's undertaking. This can be achieved with data encryption and proper media handling policies. Data retention period: Regulations and policy can lead to situations where backups are expected to be retained for a particular period, but not any further. Retaining backups after this period can lead to unwanted liability and sub-optimal use of storage media. Checksum or hash function validation: Applications that back up to tape archive files need this option to verify that the data was accurately copied.

== Descriptive inorganic chemistry == Descriptive inorganic chemistry focuses on the classification of compounds based on their properties. Partly the classification focuses on the position in the periodic table of the heaviest element (the element with the highest atomic weight) in the compound, partly by grouping compounds by their structural similarities.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

How are the two variants distinguished in a laboratory?

The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.

Network